TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30802822
Drug: Oral vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vinorelbine 80 mg/m2 (first cycle at 60 mg/m2, escalated to 80 mg/m2 in the absence of grade 3/4 toxicity)
Study: 30802822
Drug: Intravenous paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous paclitaxel 80 mg/m2 on days 1, 8, and 15 every 3 weeks
Study: 30802822
Drug: Intravenous paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous paclitaxel
Study: 24076689
Drug: External valvuloplasty
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External valvuloplasty for small subcutaneous veins
Study: 21880848
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and vitamin D (1 g Ca/400 IU vitamin D daily)
Study: 16446329
Drug: 90Y‐muHMFG1 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90Y‐muHMFG1 plus standard treatment
Study: 11866284
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose HBV vaccination (40 microg administered monthly for 3 months)
Study: 11866284
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose HBV vaccination (booster dose of 80 microg for nonresponders)
Study: 9642936
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of inactivated influenza vaccine
Study: 9642936
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of inactivated influenza vaccine
Study: 335348
Drug: H. influenzae
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. influenzae type b vaccine
Study: 335348
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (group A meningococcal vaccine)
Study: 26456573
Drug: Paclitaxel 90
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 90 mg/m² IV (days 1, 8, and 15) and bevacizumab 10 mg/kg IV (days 1, 15) with everolimus 10 mg daily (Arm 1)
Study: 26456573
Drug: Paclitaxel 90
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 90 mg/m² IV (days 1, 8, and 15) and bevacizumab 10 mg/kg IV (days 1, 15) with placebo (Arm 2)
Study: 23245582
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg IV iron sucrose
Study: 23245582
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg IV iron sucrose
Study: 23245582
Drug: 2.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg/kg IV iron sucrose
Study: 19393845
Drug: ketoprofen 100
Normalized name: ketoprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketoprofen 100 mg + acetaminophen 1000 mg
Study: 19393845
Drug: ketoprofen 100
Normalized name: ketoprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketoprofen 100 mg
Study: 15669418
Drug: Intravenous propafenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propafenone (IV bolus of 2mg/kg in 15 minutes, followed by maintenance infusion of 0.0067 mg/kg/min until conversion to sinus rhythm or for up to 90 minutes)
Study: 15669418
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching saline solution administered in the same fashion)
Study: 11211369
Drug: Imipramine combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine combined with cognitive-behavioral therapy
Study: 11211369
Drug: Placebo combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo combined with cognitive-behavioral therapy
Study: 11211369
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (including psychotropic medication and outpatient therapy)
Study: 9368196
Drug: Citalopram infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram infusion (20 mg i.v. at 14:20-14:50 h) after a night of undisturbed sleep
Study: 9368196
Drug: Citalopram infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram infusion (20 mg i.v. after a night of sleep deprivation
Study: 27537603
Drug: Kestose, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kestose, administered orally every day for 12 weeks
Study: 24330422
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A (100,000 IU for infants <12 months & 200,000 IU for children >12 months) and 10 mg daily zinc for 6 months
Study: 17383342
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg/day) for 3 weeks before surgery
Study: 15102997
Drug: Uracil-tegafur (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uracil-tegafur (250 mg of tegafur per square meter of body-surface area per day) for two years
Study: 11476795
Drug: 17alpha-hydroxyprogesterone caproate
Normalized name: 17alpha-Hydroxyprogesterone hexanoate
DrugBank: Hydroxyprogesterone caproate (DB06789)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17alpha-hydroxyprogesterone caproate (17-HPC) 341 mg every 3 days
Study: 11476795
Drug: Intramuscular progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular progesterone (P) 50 mg daily
Study: 7975797
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (Fragmin) - 2500‐5000 anti‐Xa‐units once daily for 10 days
Study: 7975797
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (Liquemin) - 5000 IU two to three times daily for 10 days
Study: 7975797
Drug: Heparin induced
Normalized name: HIT (Heparin induced thrombocytopenia) antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin induced thrombocytopenia
Study: 2692199
Drug: Intravenous prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous prostaglandin E1 (PGE1) - 60 micrograms, 3 ampoules, infused daily over 3 hours for 6 weeks
Study: 2692199
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - 3 ampoules of alpha-CD, infused daily over 3 hours for 6 weeks
Study: 30054906
Drug: Adequate hydration
Normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adequate hydration with nitrates (isosorbide dinitrate combined with isotonic saline at 1.5 mL/kg/h during perioperative period)
Study: 25952653
Drug: Telemonitoring intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telemonitoring intervention (home BP telemonitors, medication adjustments by pharmacists, lifestyle advice via telephone visits)
Study: 19595382
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA supplementation (2.4 g/d)
Study: 11566079
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine (15 mg) plus fentanyl (25 microgram)
Study: 11566079
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine (15 mg) alone
Study: 2979276
Drug: Liquid antacid
Normalized name: GNP Liquid Antacid Maximum Strength 400mg-400mg-40mg/5ml Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid antacid (neutralizing capacity 120 mmol per day)
Study: 2979276
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g cimetidine
Study: 2979276
Drug: Placebo pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pain tablets
Study: 2979276
Drug: 4 weeks
Normalized name: risperiDONE 75 mg/4 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weeks of therapy (general)
Study: 31430366
Drug: Antibiotic Review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic Review Kit (ARK) intervention
Study: 9513749
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) infusion of TRP 100 mg/kg
Study: 3050616
Drug: Defibrotide (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide (800 mg/i.v.)
Study: 3050616
Drug: Calcium heparin
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium heparin (15,000 UI/s.c.)
Study: 3050616
Drug: Defibrotide (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide (800 mg/i.v.) and Calcium heparin (15,000 UI/s.c.)
Study: 27915408
Drug: Copanlisib 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copanlisib 0.4 mg/kg
Study: 27915408
Drug: Copanlisib 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copanlisib 0.8 mg/kg
Study: 27915408
Drug: Copanlisib (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copanlisib (both doses)
Study: 31257614
Drug: Risankizumab 18
Normalized name: RISANKIZUMAB 180 mg in 1.2 mL SUBCUTANEOUS INJECTION, SOLUTION [Skyrizi]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab 18 mg SC
Study: 31257614
Drug: Risankizumab 90
Normalized name: Risankizumab 90.361 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab 90 mg SC
Study: 31257614
Drug: Risankizumab 300
Normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Risankizumab 300 mg SC
Study: 31257614
Drug: Risankizumab 200
Normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Risankizumab 200 mg IV
Study: 31257614
Drug: Risankizumab 600
Normalized name: RISANKIZUMAB 600 mg in 10 mL INTRAVENOUS INJECTION [Skyrizi]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab 600 mg IV
Study: 31257614
Drug: Risankizumab 1200
Normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Risankizumab 1200 mg IV
Study: 31257614
Drug: Risankizumab 75
Normalized name: risankizumab 75 mg/0.83 mL subcutaneous kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab 75 mg SC
Study: 31257614
Drug: Risankizumab 150
Normalized name: RISANKIZUMAB 150MG/ML ON-BODY KIT 2.4ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab 150 mg SC
Study: 29912798
Drug: encenicline 1
Normalized name: Encenicline
DrugBank: Encenicline (DB11726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: encenicline 1 mg twice daily
Study: 29912798
Drug: encenicline 1
Normalized name: Encenicline
DrugBank: Encenicline (DB11726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: encenicline 1 mg twice daily + NRT patch
Study: 29912798
Drug: placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo + NRT patch
Study: 29912798
Drug: encenicline plus
Normalized name: Encenicline
DrugBank: Encenicline (DB11726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: encenicline plus placebo patch
Study: 17667331
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available individual dosage forms (reference treatment)
Study: 15780109
Drug: B vitamin
Normalized name: B-50 Hi Potency B Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: B vitamin supplementation (1 mg of folic acid, 10 mg pyridoxal 5'-phosphate, and 6 µg of vitamin B12)
Study: 20378616
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (buserelin)
Study: 7797602
Drug: Famotidine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (40 mg/day, oral)
Study: 759664
Drug: Breast cancer
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast cancer treatment
Study: 28763451
Drug: Stepped-care program
Normalized name: PEPPLUS SPECIAL SKIN CARE LIFTING PROGRAM KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped-care program delivered by trained practice nurses over one year, consisting of watchful waiting, guided self-help, problem solving treatment, and referral to the general practitioner.
Study: 26469750
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (30 mg DHA/kg/d)
Study: 22035986
Drug: TARGET (trauma
Approvals — FDA: no, EMA: no, PMDA: no
Description: TARGET (trauma affect regulation: guide for education and therapy)
Study: 22035986
Drug: PCT (present
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCT (present centered therapy)
Study: 18957532
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg simvastatin daily for 8 weeks
Study: 15531767
Drug: Trandolapril at
Normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trandolapril at a target dose of 4 mg per day
Study: 11309014
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 and 0.9 mg/kg
Study: 9444014
Drug: Mebendazole 25
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mebendazole 25 mg single dose
Study: 9444014
Drug: Mebendazole 50
Normalized name: mebendazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole 50 mg single dose
Study: 9444014
Drug: Mebendazole 75
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mebendazole 75 mg single dose
Study: 9444014
Drug: Mebendazole 100
Normalized name: mebendazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole 100 mg twice daily for 3 days
Study: 27002108
Drug: tofacitinib 10
Normalized name: tofacitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tofacitinib 10 mg twice daily + MTX
Study: 27002108
Drug: tofacitinib 10
Normalized name: tofacitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tofacitinib 10 mg twice daily (monotherapy)
Study: 27002108
Drug: MTX +
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX + placebo (MTX monotherapy)
Study: 24645942
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment in the intensive care unit (control group)
Study: 15829527
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (2000 IU daily)
Study: 7554523
Drug: Nitrendipine 2
Normalized name: nitrendipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 2 x 5 mg daily (normotensive group)
Study: 7554523
Drug: Nitrendipine 2
Normalized name: nitrendipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 2 x 10 mg - 2 x 20 mg daily (hypertensive group)
Study: 7356905
Drug: Indoprofen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoprofen (200 mg)
Study: 7356905
Drug: Ibuprofen (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (300 mg)
Study: 30935539
Drug: Nano-curcumin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nano-curcumin supplementation (80 mg for 8 weeks)
Study: 20816118
Drug: Fenofibrate/pravastatin combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate/pravastatin combination therapy
Study: 21973199
Drug: Pravastatin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin monotherapy
Study: 18584924
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care treatment (generic education only) (n=23)
Study: 10838741
Drug: Triple-drug therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-drug therapy without change (group B)
Study: 8255478
Drug: Tolcapone (Ro
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolcapone (Ro 40-7592) administered in combination with levodopa/carbidopa
Study: 26997218
Drug: 250 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mL 20% mannitol and 1 L 0.9% saline orally at 20:00 hours on the day before and at 05:00 hours on the day of CE and 20 mL simethicone 30 min before CE
Study: 22444242
Drug: Novel dose-response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Novel dose-response models considering spatial distribution of radiation dose
Study: 22444242
Drug: Minimising dose
Normalized name: homatropine hydrobromide Ophthalmic Solution [Minims Homatropine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimising dose to the lateral and cranial component of the human parotid gland
Study: 20534288
Drug: Once-daily everolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily everolimus administration
Study: 20534288
Drug: Twice-daily everolimus
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily everolimus regimen
Study: 20534288
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (once-daily and twice-daily)
Study: 16088114
Drug: 1,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 IU ergocalciferol daily
Study: 8754325
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg slow release verapamil once daily
Study: 1864092
Drug: Oral acyclovir,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acyclovir, 800 mg 5 times daily
Study: 6749352
Drug: Verapamil 120
Normalized name: verapamil 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 120 mg three times a day for 6 months
Study: 24995659
Drug: Classical GON
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classical GON block with 10 mg dexamethasone + 40 mg lidocaine (5 mL volume)
Study: 24995659
Drug: Subcompartmental GON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcompartmental GON block with 10 mg dexamethasone + 40 mg lidocaine + nonionic iodine contrast + saline (5, 10, or 15 mL volume)
Study: 9428499
Drug: Intermediate dose
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate dose systemic methotrexate (IV‐MTX) with IT‐MTX
Study: 18520310
Drug: Copayment policy
Normalized name: Polivy
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Copayment policy for prescription drugs
Study: 16033298
Drug: Fixed-dose rosiglitazone/metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose rosiglitazone/metformin 8 mg/2g per day
Study: 16033298
Drug: Metformin 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 3 g/day
Study: 14709951
Drug: St. John's
Normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St. John's wort extract (255 to 285 mg, 900 microg hypericin content)
Study: 11471516
Drug: Non-drug measures
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-drug measures
Study: 9568701
Drug: Enalapril treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril treatment for 12 weeks
Study: 19225403
Drug: 1‐mg/kg propofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1‐mg/kg propofol
Study: 19225403
Drug: 0.2‐mg/kg etomidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2‐mg/kg etomidate
Study: 16782098
Drug: Cox‐2 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cox‐2 inhibitor treatment
Study: 11156863
Drug: 1 mg/d
Normalized name: Lyllana 0.1 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/d 17ss‐estradiol continuously plus 0.025 mg gestodene for 12 days every month (standard‐progestin group)
Study: 11156863
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg 17ss‐estradiol plus 0.025 mg gestodene for 12 days every third month (low‐progestin group)
Study: 9225834
Drug: Dextrose 5%
Normalized name: Dextrose 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose 5% 600 to 800 kcal.d‐1 plus recombinant human growth hormone (DX + rGH)
Study: 24073815
Drug: Cognitive narrative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive narrative intervention (4 weekly 60-min sessions)
Study: 20354500
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection in the blood cardioplegic solution
Study: 20354500
Drug: 4 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mmol/L of L-arginine in the blood cardioplegic solution
Study: 20354500
Drug: 6 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mmol/L of L-arginine in the blood cardioplegic solution
Study: 16203878
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment with immobilization in a below-the-elbow plaster cast (44 patients)
Study: 10087407
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg progesterone b.i.d. by the vaginal route (Esolut, Angelini) starting on the day of oocyte pick up (Group A, n = 15)
Study: 10087407
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg intramuscular progesterone once daily (Prontogest, Amsa) (Group B, n = 15)
Study: 7608310
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of moexipril
Study: 7608310
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg of moexipril
Study: 27840443
Drug: Focused shockwave
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focused shockwave therapy (FSWT; 2000 impulses, 4 Hz, 0.4 mJ/mm2)
Study: 27840443
Drug: Radial shockwave
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial shockwave therapy (RSWT; 2000 impulses, 8 Hz, 5 bars + 2000 impulses, 8 Hz, 2.5 bars)
Study: 27840443
Drug: Focused shockwave
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focused shockwave therapy (FSWT)
Study: 26406193
Drug: Radial shockwave
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial shockwave therapy (RSWT)
Study: 25402398
Drug: iDecide (interactive,
Approvals — FDA: no, EMA: no, PMDA: no
Description: iDecide (interactive, Web-based, tablet computer-delivered tool)
Study: 23146640
Drug: Slow IANB
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow IANB with 3.6 mL of 2% lidocaine with 1:200,000 epinephrine
Study: 23146640
Drug: Rapid IANB
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid IANB with 3.6 mL of 2% lidocaine with 1:200,000 epinephrine